ERBB2 and breast cancer: Among patients with estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer, progesterone receptor (PR)-negative tumors were shown to have worse prognosis than PR-positive tumors [1–3].